Phaseline

Companies › Hebei Senlang Biotechnology

Hebei Senlang Biotechnology: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
S1904 CD19 CAR-T
Autologous CD19-targeting CAR-T cells
–Phase 2B-ALLMar 2027
Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
Multi-target CAR-T cells targeting CD19, CD20, and CD22
CD19, CD22, CD20Phase 119 and 22+ B Cell Hematologic TumorsMar 2027
SENL101
CD7-targeting CAR-T cell therapy
CD7Phase 1T-lymphoblastic LymphomaAug 2038

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05388695Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cellsPhase 119 and 22+ B Cell Hematologic TumorsOncologyMar 2027
NCT07244406S1904 CD19 CAR-TPhase 2B-ALLOncologyMar 2027
NCT06136364SENL101Phase 1T-lymphoblastic LymphomaOncologyAug 2038

Targets

CD19 (1) CD22 (1) CD20 (1) CD7 (1)

Companies with the same targets

Gilead Sciences AstraZeneca Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Roche Cellectis Lyell Immunopharma Amgen

Companies built like this

PersonGen BioTherapeutics (Suzhou) Beijing Yongtai Ruike Biotechnology Company Allotera Therapeutics Hrain Biotechnology Marzieh Ebrahimi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.